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insulin delivery†
Clarinda Costa, ‡a,b,c Zehua Liu,‡a João P. Martins,a Alexandra Correia,a
Patrícia Figueiredo,a Antti Rahikkala,a Wei Li, a Jani Seitsonen,d
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Here, a continuous two-step glass-capillary microfluidic technique
to produce a multistage oral delivery system is reported. Insulin is
successfully encapsulated into liposomes, which are coated with
chitosan to improve their mucoadhesion. The encapsulation in an
enteric polymer offers protection from the harsh gastric con-
ditions. Insulin permeability is enhanced across an intestinal
monolayer.
The oral route of administration represents the most con-
venient way to administer drugs in terms of high patient
compliance,1,2 promoting a fast and safe route, overcoming
several main disadvantages from parenteral administration
namely intravenous administration.3–6 However, the oral deliv-
ery of therapeutic proteins and peptides represents a big chal-
lenge for the pharmaceutical technology field. In fact, the
degradation of proteins and peptides under acidic conditions
in the stomach concomitantly with digestive enzyme action, as
well as the poor oral bioavailability, characterized by a poor
protein permeability in the intestinal epithelium7–9 has led to
the need for designing and developing alternative approaches
to enhance the oral protein/peptide administration.10–12 Over
the last decade, the research for different strategies for the oral
delivery of proteins and peptides, such as microemulsions,13,14
polymeric nanoparticles,8,9,16 silicon nanoparticles15,17,18 and
liposomes,19,20 has been significantly increasing. Liposomes,
introduced for the first time by Bangham et al.21 at the begin-
ning of the 1960s, have been described as potential protein
and peptide drug carriers able to enhance their blood resi-
dence time and targeting.22–24 However, even with high poten-
tial to deliver proteins, conventional liposomes are still likely
to disintegrate under gastric conditions25,26 and can show
poor permeation across the intestinal epithelial cell mem-
brane,27 thus resorting to coatings with other molecules, such
as polymers28,29 or protein corona.30,31 Yet, liposomes are
usually prepared by bulk methods such as thin-film
hydration,32,33 ethanol injection,34 and reverse phase
evaporation,35,36 in which some of them require a post-proces-
sing step to obtain a better control of size and polydispersity
index (PDI), such as high pressure extrusion.37
Microfluidics, a sophisticated technique for particle pro-
duction, has gained substantial attention to prepare lipo-
somes. High batch-to-batch reproducibility, reduced time
and cost, and increased control on the production of nano-
particles are some of the advantages of microfluidics.38–40
Polydimethylsiloxane (PDMS)-based microfluidic devices are
widely used in liposome preparation. PDMS is compatible with
some pharmaceutical grade solvents, such as ethanol.41
However, PDMS microfluidic devices have low resistance to
high flow rates and pressures and, upon contact with common
organic solvents, tend to swell. In addition, due to the hydro-
phobicity of the polymer, post-surface functionalization of the
polymer is required.42–44 Attending to these drawbacks, glass-
capillary microfluidic devices are a good alternative when
there is the need to use organic solvents. Besides, they can tol-
erate high flow rates and pressures.45 Glass-capillary microflui-
dic devices enable the production of liposomes through a
nanoprecipitation method.46,47 If a central flow of a phospholi-
pid-containing alcohol solution merges into a main channel
with the aqueous solution in adequate concentrations, the
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lipids spontaneously self-assemble, producing liposomes,48
with diameters in the range of 73–131 nm, as described by
Vladisavljevic et al.49 Moreover, these devices enable the gene-
ration of monodisperse droplets via co-flow or coaxial flow-
focusing geometry or via the combination of both
geometries,45,50 offering an excellent control of the size of the
droplets by adjusting the flows of immiscible fluids inside the
microchannels and the dimensions of the orifices of the
channels.51,52 By the solidification of the monodisperse dro-
plets, microparticles with an uniform size distribution can be
produced.53 In this way, using glass-capillary microfluidic
devices both nano- and nano-in-microparticles can be
obtained, which represents a huge advantage for oral adminis-
tration since microparticles have been described as preferable
for this kind of administration compared to nano-sized
systems.54 Besides, microparticles are more attractive for oral
delivery over the conventional larger capsules or pill-type
vehicles due to the patient compliance and convenience,
especially in children that have some difficulties in swallowing
larger pills or capsules.55,56
In this work, we present an optimized and continuous “all-
in-one” two-step microfluidic production of a nano-in-micro
composite system, as shown in Fig. 1A. Firstly, the microfluidic
parameters, such as flow rate ratio (FRR), initial lipid concen-
tration and total flow rate, were optimized in order to prepare
liposomes with a size between 100 and 150 nm and an accep-
table narrow PDI (<0.2). To assess the influence of the FRR
(the ratio between the aqueous and the organic phases) on the
size and PDI of the liposomes, the microfluidic parameters
outer flow rate and initial lipid concentration were kept con-
stant (outer flow rate = 20 mL h−1 and initial lipid concen-
tration = 43.2 µmol mL−1). The FRR was varied between 1 and
Fig. 1 Preparation and characterization of Lip and Ins@MPs. (A) Schematic representation of the two-step microfluidic process of insulin-loaded
nano-in-microparticles (not to scale), in which insulin is encapsulated in PEGylated liposomes (InsLip) through a nanoprecipitation technique, using
a glass-capillary microfluidic device. The InsLip-CHT were further encapsulated in an enteric polymer (MF) using a double-emulsion microfluidic
process, forming the final microcarrier system (Ins@MPs). (B) Size (bar) and PDI (red squared dots) of liposomes on the optimization of the microflui-
dic parameters for liposome production: a. flow rate ratio, keeping constant the total flow rate (TFR) of 20 mL h−1 and initial lipid composition (ILC)
of 43.2 µmol mL−1; b. TFR, keeping fixed the FRR of 1 and ILC of 43.2 µmol mL−1 and c. initial lipid concentration (µmol mL−1), keeping fixed the FRR
of 1 and TRF of 20 mL h−1. The orange line represents the maximum PDI value acceptable for liposomes (0.2). The level of significance was set at the
probabilities of **p < 0.01 and ***p < 0.001. (C) Cryo-TEM images of liposomes, using the optimized microfluidic parameters described above. (D)
ATR-FTIR spectra of MF and insulin-loaded nano-in-microparticles (Ins@MPs). Black arrows: bands from chitosan chemical groups; red arrows:
bands from MF chemical groups.
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10 (Fig. 1B(a)). As expected, increasing the FRR reduces the
size of the liposomes.41,57 This phenomenon can be related to
the non-equilibrium kinetic model described by Zook and
Vreeland.57 This kinetic model applied to liposomes suggests
that the size of the liposomes is closely related to the growth
rate of the lipid planar discs (bilayered phospholipid frag-
ments (BPFs)) and to the closing rate of the discs into spheri-
cal vesicles. In this way, the model predicts that at higher
FRRs, the alcohol concentration decreases faster and the lipid
disc growth rate decreases. In addition, since BPFs grow with
less stabilization, the lipid discs close faster, producing
smaller liposomes. In contrast, at lower FRRs, the BPFs take
more time to grow, and due to the stabilization from the
alcohol stream, they take more time to close, making the lipo-
somes larger.37,57 The optimization was pursued towards the
study of the effect of the total flow rate (TFR) on the morpho-
logical properties of the liposome. The TFR was varied
between 10 and 100 mL h−1, while the FRR was kept at 1 and
the initial lipid concentration at 43.2 µmol mL−1. Fig. 1B(b)
shows that the TFR has no significant effect (p > 0.05) on the
size of the liposomes, which is in accordance with previous
studies.58,59 This represents an advantage of the scalable
microfluidics – increasing the throughput does not affect sig-
nificantly the liposome size. Likewise, it does not affect the
PDI, which remained below 0.2. Thus, since the desired size
and acceptable PDI were obtained with a total flow rate of
20 mL h−1, the studies were pursued with a lipid concentration
of 43.2 µmol mL−1 and a total flow rate of 20 mL h−1. As the
lipid concentration plays an important role in the morphology
of the liposomes, the initial lipid concentration was varied
from 20.8 to 54.0 µmol mL−1 (the total flow rate was kept at
20 mL h−1 and the FRR was kept at 1). Fig. 1B(c) shows an
increase of the size of the liposomes with the increase of lipid
concentration. Upon contact with the aqueous solution, the
alcohol, in which the lipids were initially solubilized, diffuses
into the water, leading to a lipid supersaturation.57 Similar to
the FRR, the intermediate lipid discs, described as BPFs, are
formed in the ethanol/water interface and are thermo-
dynamically less stable. When the BPFs grow, they tend to fuse
and enclose into a vesicle;60 thus, higher lipid concentrations
can produce more BPFs, enabling the generation of larger vesi-
cles. An initial lipid concentration of 43.2 µmol mL−1 was
selected to pursue the experiments. Cryo-TEM was performed
in order to confirm the morphology/structure of the InsLip
nanoparticles. For the optimized parameters, the cryo-TEM
images show a thin single-wall structure enclosing a vesicle,
confirming that the structure of the nanoparticles corresponds
to that of liposomes, with a mean size of 110 ± 20 nm, simi-
larly to the values obtained by DLS (Fig. 1C(a)). In addition,
using Gatan Microscopy Suite software, it was possible to
measure the thickness of the bilayer of the liposomes, which
was around 6 ± 1 nm (Fig. 1C(b)).
The encapsulation of insulin in liposomes was then carried out
with the previous optimized parameters. Recombinant human
insulin (Ins) was first dissolved in a citrate solution, at pH 2.0, at a
concentration of 100 µg mL−1 (outer phase), whereas lipids (egg-
phosphatidylcholine (E-PC) and distearoylphosphatidylethanola-
mine poly(ethyleneglycol)2000 (DSPE-PEG2000)) and cholesterol were
dissolved in ethanol at a concentration of 43.2 µmol mL−1 (inner
phase). Through a nanoprecipitation phenomenon,47 lipids upon
contact with the citrate solution self-assembled, forming protein-
loaded PEGylated liposomes (InsLip). After being collected from
the glass capillary, InsLip were characterized in terms of hydrodyn-
amic size, PDI, and encapsulation efficiency (E.E.). InsLip were
obtained with an average size of 144 ± 23 nm, a mean PDI of 0.130
± 0.003 and an E.E. of 91 ± 4%. Considering that this process is
continuous, the E.E. was calculated from the total concentration of
insulin in the liposomes and the insulin present in the super-
natant after liposome washing. During the assays no precipitated
insulin was observed. To the best of our knowledge, the E.E.
obtained represents an improvement compared to previous
studies, involving liposomes with the same morphological pro-
perties (Niu et al. presented insulin-loaded liposomes with a size
of 150 nm and an E.E. of 30%,20,27 whereas Muramatsu et al.
reported liposomes with a size between 106 and 108 nm with an E.
E. of 21.5% 61).
The physical coating of chitosan on the InsLip (InsLip-
CHT) was achieved by adding the InsLip suspension dropwise
to the chitosan solution (10 mg mL−1 in 1% of acetic acid solu-
tion (v/v), pH 5.5), at the same volume ratio, and stirring for
6 h. Then, the dispersion containing chitosan-coated lipo-
somes (InsLip-CHT) was centrifuged and washed twice. The
coating was observed by the change in the InsLip-CHT average
size and PDI, up to a mean size of 363 ± 54 nm and a PDI of
0.315 ± 0.057. In addition, the increase of the zeta-potential
from a value near to zero (−0.5 ± 0.1 mV) to a positive value
(+23 ± 1 mV) suggests the successful chitosan coating of the
liposomal surface. Since the zeta-potential of InsLip was near
zero, it is expectable that the interaction between the lipo-
somes and chitosan might have occurred by van der Waals
and hydrogen bonding forces.62
Nano-in-microparticles are mostly used for their ability to
effectively deliver higher local doses in a specific tissue.63 In
this way, through a double emulsion microfluidics method,
the nanoparticles were encapsulated in an FDA approved exci-
pient for oral administration, hydroxypropyl methylcellulose
acetate succinate (HPMCAS-MF; M grade fine powders, abbre-
viated as MF), in order to protect the liposomes against the
harsh stomach acidic conditions (Ins@MPs). MF is a synthetic
enteric polymer with an average molecular weight of around
17 000 Da and a polydispersity of approximately 1.364 and
since it presents a pKa ∼ 5, this polymer is widely used for oral
drug delivery applications.65 The encapsulation of the InsLip-
CHT in the MF matrix resulted in a batch of 15 mL of insulin-
loaded nano-in-microparticles (Ins@MPs) with a size of 19 ±
1 µm. The ATR-FTIR spectra (Fig. 1D) of Ins@MPs show a
band at 1710 cm−1, which corresponds to the CvO stretching
of the carboxylic group from MF, as well as a band at
2900 cm−1, which belongs to the C–H stretching of the alkyl
group. Nevertheless, the broad band at 3388 cm−1 and the
band at 1630 cm−1 correspond to the N–H stretching of the
amine and CvO stretching of the amides groups, respectively,
Communication Biomaterials Science
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suggesting the presence of chitosan.66,67 Apart from these
bands, the spectrum of Ins@MPs is very similar to the MF
spectra, suggesting an efficient encapsulation of InsLip-CHT
by MF. The microparticles were characterized in terms of
loading degree, which was 0.39 ± 0.02%.
Then, the release profile of the insulin was evaluated. To
mimic the gastric conditions, the Ins@MPs were dispersed for
2 h in simulated gastric fluid (SGF) at pH 1.2. Afterwards, the
microparticles were dispersed in fasted state simulated intesti-
nal fluid (FaSSIF) at pH 6.8, in order to test their behavior after
the transition from the stomach to the small intestine con-
ditions. Regarding the pH-responsiveness of MF-based micro-
particles, TEM imaging and the size measurement over the
time have shown that MF microparticles remain intact at pH
1.2, but upon pH increase to 6.8, the enteric polymer starts to
dissolve, releasing the CHT-based NPs, and after 2 h, the
polymer is completely dissolved.67–69 With respect to the pH of
the small intestine in the fed or fasted state, McConnell et al.
reported that the fed state of the animal (rats or mice) had no
significant effect on the pH.70 Thus, it is hypothesized that the
insulin release might not be affected by food intake, although
this needs to be still confirmed in the future for our particular
system. The pH-responsiveness of MF was observed in the
release studies. Fig. 2A shows that there was no release in SGF
during the first 2 h, due to the successful encapsulation in the
enteric polymer (MF) that is not soluble at a pH below 6.0.71
However, MF dissolved when the pH was changed to 6.8,
exposing InsLip-CHT to the solution, and a burst release of
7.5% of insulin was observed in the first minutes, whereas
after 24 h an insulin release up to 25% was achieved. These
results corroborate that, in this work, MF plays a relevant role
in the nanoparticle protection, since previous works have
demonstrated that in the absence of MF, at pH 1.2, insulin
would be released from CHT-based nanoparticles.67,68
Next, cell viability assays were carried out in order to evalu-
ate the toxicity of the nano-in-microparticles with and without
insulin. The intestinal cell lines Caco-2 and HT29-MTX were
used in this study. Human colon carcinoma Caco-2 cells have
been used over the years as a model of the intestinal barrier.
Upon differentiation, Caco-2 cells express similar character-
istics to the small enterocytes.72 The HT29 cells (colon adeno-
carcinoma) are frequently used as a model of epithelial cells of
the intestinal mucosa. When they are treated with methotrex-
ate (MTX), they become resistant to cytostatic drugs and an
adhesive mucus layer is formed on the apical side of a mono-
layer cell culture.73 The in vitro cytotoxicity assay was con-
ducted by exposing both cell lines to the nano-in-microparti-
cles with and without insulin for 6 and 24 h, in concentrations
ranging from 50 µg mL−1 to 1000 µg mL−1 of microparticles
(corresponding to 0.195 µg mL−1 to 0.390 µg mL−1 of insulin,
respectively) (Fig. 2B). After the first 6 h, for the Caco-2 cells,
the nano-in-microparticles without insulin did not show the
signs of cytotoxicity, with a cell viability above 80%, for all con-
centrations tested. For Ins@MPs, a cell viability decrease was
observed for the higher concentration used (1000 µg mL−1);
however, it was not statistically significant (p < 0.05).
Furthermore, after 24 h, a slight decrease in the viability of
Caco-2 cells (13% for Ins@MPs and 12% for the nano-in-
Fig. 2 (A) Insulin release profile from insulin-loaded nano-in-microparticles (Ins@MPs), in the first 2 h in SGF (pH 1.2) and then in FaSSIF (pH 6.8)
for 24 h at 37 °C. The transition from SGF to FaSSIF is represented by an orange line. (B) Caco-2 and HT29-MTX cell line viability when exposed to
different concentrations of nano-in-microparticles with and without insulin, after 6 h and 24 h of incubation at 37 °C. All the data were compared to
the negative control (HBSS–HEPES buffer, pH 7.4). (C) a. Insulin permeation profile across Caco-2 and HT29-MTX co-cultured (ratio of 9 : 1) cell
monolayers. The Ins@MPs were incubated with FaSSIF (pH 6.8) in the apical compartment and HBSS–HEPES (pH 7.4) in the basolateral compart-
ment. All the experiments were carried out for 3 h at 37 °C, using an orbital shaker at 100 rpm. b. Circular dichroism of permeated free insulin at 2.3
× 10−2 µg mL−1 (black line) and insulin from Ins@MPs at 1.1 µg mL−1 (red line), in HBSS–HEPES (pH 7.4). The level of significance was set at the prob-
abilities of *p < 0.05 and **p < 0.01. The results are expressed as mean ± S.D. (n = 3).
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microparticles) was observed at a concentration of 1000 µg
mL−1. Since at pH 6.8, the cells were exposed to the chitosan
from InsLip-CHT, this decrease in their viability can be
related to the Caco-2 cytotoxicity dependence on the chitosan
concentration, as reported in previous studies.74,75 Regarding
the HT29-MTX cell line, when the nano-in-microparticles
were in contact with cells, even at higher concentrations,
their viability remained higher than 80%, for both time
points tested. This low cytotoxicity is in accordance with
other studies reported in the literature and can be explained
by the presence of mucus on the HT29-MTX surface, which
acts as a barrier.8
Once verified the cell viability, the insulin permeability
across a monolayer was evaluated. In order to reach the blood-
stream, which is mandatory for a successful insulin drug deliv-
ery, insulin must cross from the apical to the basolateral side
of the intestinal epithelium. To closely mimic the in vivo phys-
iological intestinal environment, Caco-2 and HT29-MTX were
co-cultured for 21 days to form a monolayer.8 The Ins@MPs
were incubated with the cells for 3 h at pH 6.8 (apical compart-
ment), whereas the pH in the basolateral compartment was
kept at 7.4. The experiment was carried out using free insulin
as a control. The permeated insulin dissolved in the basolat-
eral compartment was quantified by HPLC. As observed in
Fig. 2C(a), a higher permeation was observed for the Ins@MPs
than for free insulin (Papp of 2.27 × 10
−5 cm s−1 and 1.19 ×
10−7 cm s−1, respectively). Since the pH in the apical compart-
ment was 6.8, the existing enteric polymer (MF) was dissolved,
exposing the chitosan-coated liposomes. These results are in
accordance with those of the release studies, where insulin
release occurred only at pH 6.8. At each time-point, transe-
pithelial electrical resistance (TEER) was measured (Fig. S1,
ESI†) in order to monitor the ion conductance across the
monolayers. This phenomenon is characterized by the
opening of the monolayer tight junctions. Once opened, the
ion transport across the paracellular route76,77 will be faster. In
this nanosystem, TEER values tend to decrease faster for the
Ins@MPs than for free insulin, as expected. Some studies have
reported that chitosan tends to bind with integrins from the
membrane of intestinal epithelial cells, activating a signal
pathway that involves protein kinases, such as focal adhesion
kinase (FAK) and Src tyrosine kinase.78 In turn, these kinases
induce degradation and translocation of the tight junctions
proteins, such as cytoplasmic proteins, occludin and claudins
(e.g., CLDN4).79,80 This activation mechanism promotes the
reversible opening of the tight junctions, enhancing the per-
meability of the molecules through a paracellular pathway.81
In contrast, the decrease of the TEER values observed for free
insulin, after 120 min, was not expected, since in the drug per-
meability assays, no insulin was observed in the basolateral
compartment. During the insulin permeation, it was impor-
tant to evaluate whether its activity remains the same. Thus,
far UV region circular dichroism, a tool widely used to identify
the structural secondary elements of peptides,82 was per-
formed in order to identify the α-helix and β-sheet structures
of the permeated insulin and to compare them with those of
the native form of insulin (Fig. S2, ESI†). As described else-
where, the insulin’s α-helix conformation is characterized by a
valley at 208 nm and a shoulder at 223 nm.27,83 These pro-
perties can also be clearly observed in the permeated free
insulin and insulin released from liposomes (Fig. 2C(b)). In
addition, when two insulin monomers associate themselves,
antiparallel β-structures are created. This phenomenon can be
observed through the ratio of θ208 nm/θ223 nm.
27 The insulin dis-
solved in saline citric solution at pH 2 (free-insulin) presents a
ratio of 0.949, whereas the insulin from Ins@MPs presents a
ratio of 1.035, which is close to the value of native insulin
(1.088). Therefore, regarding these observations, it is possible
to conclude that the insulin’s structure remained preserved
after being loaded into the liposomes and permeated through
the Caco-2/HT29-MTX monolayers.
In order to evaluate the Ins@MP interaction with both cell
lines (Caco-2 and HT29-MTX), confocal fluorescence
microscopy was used for qualitative analysis, in which a fluo-
rescent membrane dye, 4-(4-dihexadecylaminostyryl)-N-methyl-
pyridinium iodide (DiA), was used for imaging purposes. In
this way, the experiments were carried out with 500 µg mL−1 of
DiA-loaded liposomes (DiALip) and DiALip-loaded chitosan
nanoparticles (DiALip-CHT) for 6 h. The nanoparticles coated
with MF were not evaluated, since at this pH the polymer is
completely dissolved, as shown in the release experiments.
Fig. 3A shows the interaction of both nanoparticles with Caco-
2 cells. It is possible to observe that DiALip were not interna-
lized, only interacting with the cell’s surface. This observation
is supported by the presence of the poly(ethyleneglycol)2000
(PEG2000) in the liposomes. PEG, grafted onto the surface of
the liposomes, promotes an elevated liposome blood circula-
tion, by the decrease of macrophage recognition and
opsonization.84,85 In addition, the slightly negative charge
from DSPE-PEG2000 can promote a steric barrier with the cells,
and thus, DiALip take more time to be internalized.86 In con-
trast, the liposomes coated with chitosan were easily interna-
lized. Regarding Fig. 3A, it is possible to observe a decrease of
fluorescence intensity on InsLip-CHT. This phenomenon
might be due to the chitosan-based nanoparticle internaliz-
ation, whereas the DiALip were on the cell membrane. This
phenomenon was also observed in the quantitative flow cyto-
metry study, indicating the chitosan capability to enhance the
cellular uptake. A difference of more than 10% of the DiALip-
CHT association with the cells shows the higher interactions
of this system, compared with DiA-loaded liposomes (Fig. 3B).
Confocal images of the HT29-MTX cells (Fig. 3C) did not show
notable interactions between the cells and the nanoparticles.
However, this difference was detected in the flow cytometry
quantitative analysis (Fig. 3D). These different observations
could be due to the confocal images showing part of the
sample, whereas flow cytometry quantifies the entire sample.
In this way, regarding Fig. 3D, an uptake of over 40% of the
chitosan-coated liposomes was observed, whereas no uptake
was detected for liposomes without chitosan. This phenom-
enon was also observed in previous works69,87 and it might be
related to the chitosan mucoadhesion properties, driven by the
Communication Biomaterials Science
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electrostatic interactions between the positive charge of the
chitosan and the negative charge of mucins.88
Conclusions
In this work, a multistage oral insulin delivery system using a
two-step microfluidic process was successfully designed and
developed. Insulin was efficiently encapsulated (91 ± 4%), into
PEGylated liposomes using a microfluidic technique, overcom-
ing the common liposome batch production drawbacks and
obtaining a narrow size distribution. This allowed the success-
ful encapsulation of the nanoparticles in an enteric polymer,
preventing their degradation under harsh gastric conditions.
In vitro release studies showed insulin release starting only at
pH 6.8, above the pKa of MF, demonstrating an efficient protec-
tion under gastric acidic conditions. 2D confocal microscope
images and flow cytometry analysis supported that the
mucoadhesive properties of the nanoparticles were enhanced
by the physical coating with chitosan on the surface of the
liposomes. In addition, insulin permeability and circular
dichroism studies showed a strong improvement in the insulin
permeation across the intestinal epithelium without compro-
mising its activity, respectively. Moreover, low cytotoxicity of
the Ins@MPs in the intestinal cells was observed. Overall, we
obtained a pH-responsive mucoadhesive cell-mimicking
system for protein/peptide delivery that represents a promising
strategy for a continuous, scalable and high throughput
method to produce oral targeted systems.
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Fig. 3 (A) and (C) 2D confocal fluorescence microscope images of the interactions of DiA-loaded liposomes (DiALip) and DiA-loaded liposomes
coated by chitosan (DiALip-CHT) at a concentration of 500 µg mL−1 with Caco-2 cells and HT29-MTX cells, respectively. Blue: cell nucleus stained
with DAPI (4’,6’-diamidino-2-phenyl-indole); red: cell membranes stained with CellMask Red; green: DiA (4-(4-dihexadecylaminostyryl)-N-methyl-
pyridinium iodide)-encapsulated liposomes (scale bar: 50 µm). (B) and (D) Flow cytometry quantitative analysis of the interactions between the nano-
particles and the Caco-2 cells and HT29-MTX, respectively. The experiments were carried out at 37 °C after 6 h of incubation time. The level of sig-
nificance was set at a probability of ***p < 0.001.
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